Developer docs
API playgroundTry for free, no card

Search company profiles

AssayQuant Technologies

Full company profile

uuid00022vt

Namestring
AssayQuant Technologies
Legal namestring
AssayQuant Technologies, Inc.
Websiteurl
assayquant.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

AssayQuant Technologies is a privately held biotechnology company founded in 2015 and headquartered in Marlborough, Massachusetts, that develops and commercializes continuous enzyme activity assays for kinase and phosphatase drug discovery. Its core technology is the patented PhosphoSens platform, which uses proprietary Sox-based fluorescent sensor peptide substrates to convert phosphorylation events directly into continuous fluorescence readouts, generating real-time progress curves in every well rather than single endpoint measurements. The platform is delivered through three assay formats—PhosphoSens-Kinetic (continuous fluorescence intensity for kinetic insight), PhosphoSens-Red (time-resolved fluorescence for high-throughput screening), and PhosphoSens-Lysate (for unfractionated cell and tissue lysates)—and is supported by a catalog of 1,100+ active recombinant enzymes covering 510+ wild-type kinases, 420+ mutant kinases, 55+ lipid kinases, and 35+ phosphatases.

The company operates a dual business model combining catalog reagent sales and contract research services. Assay kits, substrates, and recombinant enzymes are sold directly through the company's e-commerce storefront and via global distributors under quote-based pricing with Net 30 terms. Complementing the catalog business, KinSight Services apply the same PhosphoSens technology in AssayQuant's laboratory to deliver kinase selectivity profiling (400+ wild-type kinases), phosphatase selectivity profiling, time-dependent inhibition characterization, compound testing, and custom assay development for pharmaceutical and biotechnology drug discovery teams. Customer segments include pharmaceutical companies, biotechnology companies, and academic research institutions engaged in kinase and phosphatase inhibitor discovery from target validation through preclinical testing.

The company is founder-led, with Erik Schaefer serving as Co-Founder, President, CEO, and CSO, and Barbara Imperiali as co-founder and CTO. It has raised approximately $9.6 million across two exempt securities offerings in May 2021 and July 2023, and operates with an 11-50 employee base from its Delaware-incorporated entity.

Short descriptiontext

AssayQuant Technologies develops continuous real-time kinase and phosphatase activity assays using its patented PhosphoSens fluorescent sensor peptide platform, selling assay kits, recombinant enzymes, and KinSight profiling services to pharmaceutical, biotechnology, and academic drug discovery teams.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMarlborough, United States
HQ citystring
Marlborough
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
kinase activity assays, phosphatase profiling services, recombinant enzymes catalog, continuous fluorescence assays, drug discovery reagents
Industry2 codes
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Drug Discovery Biochemical Assay Reagents
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Assay Kit and Reagent Sales
TypeOne Time License
Description

Sale of biochemical kinase and phosphatase activity assay kits, sensor substrates, and recombinant enzymes. Products include PhosphoSens-Kinetic, PhosphoSens-Red, and PhosphoSens-Lysate formats along with enzyme reagents.

assayquant.com
2KinSight Services
TypeProfessional Services
Description

Contract research services for compound profiling including kinase selectivity profiling (400+ WT kinases), phosphatase selectivity profiling, time-dependent inhibition characterization, compound testing, and custom assay development.

assayquant.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure
Pricing details1 tier
1Catalog assay products available for direct purchase
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Products available via catalog ordering system. Quote-based pricing with 'Request a Quote' contact mechanism. No public pricing listed on website.

assayquant.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1PhosphoSens
Description

Core technology platform for continuous enzyme activity measurement using fluorescent sensor peptide substrates

assayquant.com
+1 more record
Core offering1 text field

AssayQuant Technologies develops and sells continuous kinetic biochemical assay products and contract research services for kinase and phosphatase drug discovery. Its core offering is the PhosphoSens Technology platform—fluorescent sensor peptide substrates that convert phosphorylation events into real-time fluorescent readouts—delivered through assay kits (PhosphoSens-Kinetic, PhosphoSens-Red, PhosphoSens-Lysate), a catalog of 1,100+ recombinant enzymes, and KinSight profiling services for compound selectivity and mechanism-of-inhibition characterization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Real-time measurement captures inhibitor dynamics and reversibility mechanisms not visible in endpoint reads
Product overview1 text field

AssayQuant Technologies offers a platform-plus-products architecture built on its proprietary PhosphoSens® Technology, which uses fluorescent sensor peptide substrates for continuous real-time measurement of kinase and phosphatase activity. The core platform is delivered through two assay formats: PhosphoSens-Kinetic (continuous fluorescence intensity for kinetic insight) and PhosphoSens-Red (time-resolved fluorescence for high-throughput screening), both supported by PhosphoSens-Lysate for cell/tissue lysate applications. These assay formats are available as individual product lines (Kinase Assays, Phosphatase Assays, Lysate Assays) and as part of a comprehensive recombinant enzyme portfolio spanning 900+ active kinases and 35+ phosphatases. Complementing the product catalog, KinSight Services apply the same PhosphoSens technology in AssayQuant's laboratory for compound profiling, selectivity assessment, and time-dependent inhibition characterization across hundreds of enzyme targets.

Product and service12 records
1PhosphoSens-Kinetic Assays
CategoryBiochemical Assay Kits
Description

Continuous fluorescence intensity assay kits that generate real-time kinetic progress curves of kinase and phosphatase activity in every well, enabling drug discovery researchers to characterize inhibitor potency, reversibility, and mechanism of action.

2PhosphoSens-Red Assays
CategoryBiochemical Assay Kits
Description

Time-resolved fluorescence assay kits optimized for high-throughput screening of compound libraries against kinase and phosphatase targets with reduced background interference.

3PhosphoSens-Lysate Assays
CategoryBiochemical Assay Kits
Description

Continuous fluorescence assay kits for measuring kinase activity and cell signaling directly in unfractionated cell or tissue lysates and tissue homogenates without prior fractionation.

4Kinase Assays
CategoryBiochemical Assay Kits
Description

Catalog line of validated kinase assay kits and reagents using PhosphoSens technology for real-time activity and inhibition measurement across multiple kinase targets and product configurations.

5Phosphatase Assays
CategoryBiochemical Assay Kits
Description

Catalog line of continuous, real-time phosphatase activity assay kits with multiple configurations and customizable reagent options for drug discovery applications.

6Lysate Assays
CategoryBiochemical Assay Kits
Description

Catalog line of assays using continuous fluorescence to measure kinase activity and cell signaling directly in unfractionated cell lysates and tissue homogenates.

7Recombinant Enzymes
CategoryRecombinant Enzymes and Reagents
Description

High-purity, assay-validated recombinant kinase and phosphatase enzyme catalog (510+ wild type protein kinases, 420+ mutant protein kinases, 55+ lipid kinases, 35+ protein phosphatases) designed for integration with PhosphoSens assays in basic research and preclinical drug discovery.

8KinSight Kinase Selectivity Profiling
CategoryContract Research Services
Description

Contract research service that screens compounds against a panel of 400+ wild type protein kinases using continuous real-time PhosphoSens assays to characterize compound selectivity and mechanism of action.

9KinSight Phosphatase Selectivity Profiling
CategoryContract Research Services
Description

Contract research service that measures compound potency and selectivity across phosphatase targets using continuous enzyme activity assays.

10Time-Dependent Inhibition Characterization
CategoryContract Research Services
Description

Contract research service that quantifies inhibition kinetics and provides real-time data on inhibitor potency, reversibility, residence time, and inactivation kinetics using PhosphoSens assays.

11Compound Testing Services
CategoryContract Research Services
Description

Laboratory service for testing client-supplied compounds using PhosphoSens technology assays to measure compound potency and mechanism of inhibition.

12Custom Assay Development
CategoryContract Research Services
Description

Bespoke service that develops tailored kinase or phosphatase assays against client-specified targets in requested formats using the PhosphoSens technology.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Offers KINOMEscan and related biochemical kinase/phosphatase profiling services and assays. Direct competitor to AssayQuant's KinSight selectivity profiling and kinase assay catalog.

TypeDirect peer
Description

Provides kinase and phosphatase selectivity profiling services, including time-dependent inhibition characterization. Highly comparable to AssayQuant's KinSight offering in target classes and use cases.

3Carna Biosciences
TypeDirect peer
Description

Sells recombinant kinases, kinase assay kits, and kinase profiling services. Directly comparable to AssayQuant on recombinant enzyme portfolio and biochemical kinase assay product lines.

TypeDirect peer
Description

Supplies recombinant enzymes, biochemical assay kits, and custom assay development services for kinase and other drug-discovery targets. Closely comparable to AssayQuant's product and custom assay service mix.

TypeDirect peer
Description

Develops and sells recombinant kinases, assay kits, and profiling services. Overlaps directly with AssayQuant's enzyme catalog and kinase assay reagents.

TypeBroad incumbent
Description

Large life-science tools vendor offering kinase assay kits (e.g., ADP-Glo) and biochemical reagents. Competes in the same customer workflows but as part of a much broader portfolio.

TypeBroad incumbent
Description

Successor to PerkinElmer's life sciences business, offering HTRF and LANCE kinase assay technologies. Competes directly with PhosphoSens formats in pharma screening labs.

TypeBroad incumbent
Description

Sells SelectScreen kinase profiling services, LanthaScreen and Z'-LYTE kinase assay kits, and recombinant kinases. Competes across AssayQuant's product and service lines as part of a much larger portfolio.

TypeBroad incumbent
Description

Global CRO including Eurofins DiscoverX with broad kinase/phosphatase profiling capabilities. Competes with KinSight services but operates at significantly larger scale.

10MilliporeSigma (Merck KGaA Life Science)
TypeBroad incumbent
Description

Supplies kinase assay kits, recombinant enzymes, and profiling services through its life-science portfolio. Competes with AssayQuant in both catalog reagents and CRO services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AssayQuant Technologies

Drug Discovery Biochemical Assay Reagentsassayquant.com

AssayQuant Technologies develops continuous real-time kinase and phosphatase activity assays using its patented PhosphoSens fluorescent sensor peptide platform, selling assay kits, recombinant enzymes, and KinSight profiling services to pharmaceutical, biotechnology, and academic drug discovery teams.

What AssayQuant Technologies does

AssayQuant Technologies is a privately held biotechnology company founded in 2015 and headquartered in Marlborough, Massachusetts, that develops and commercializes continuous enzyme activity assays for kinase and phosphatase drug discovery. Its core technology is the patented PhosphoSens platform, which uses proprietary Sox-based fluorescent sensor peptide substrates to convert phosphorylation events directly into continuous fluorescence readouts, generating real-time progress curves in every well rather than single endpoint measurements. The platform is delivered through three assay formats—PhosphoSens-Kinetic (continuous fluorescence intensity for kinetic insight), PhosphoSens-Red (time-resolved fluorescence for high-throughput screening), and PhosphoSens-Lysate (for unfractionated cell and tissue lysates)—and is supported by a catalog of 1,100+ active recombinant enzymes covering 510+ wild-type kinases, 420+ mutant kinases, 55+ lipid kinases, and 35+ phosphatases.

The company operates a dual business model combining catalog reagent sales and contract research services. Assay kits, substrates, and recombinant enzymes are sold directly through the company's e-commerce storefront and via global distributors under quote-based pricing with Net 30 terms. Complementing the catalog business, KinSight Services apply the same PhosphoSens technology in AssayQuant's laboratory to deliver kinase selectivity profiling (400+ wild-type kinases), phosphatase selectivity profiling, time-dependent inhibition characterization, compound testing, and custom assay development for pharmaceutical and biotechnology drug discovery teams. Customer segments include pharmaceutical companies, biotechnology companies, and academic research institutions engaged in kinase and phosphatase inhibitor discovery from target validation through preclinical testing.

The company is founder-led, with Erik Schaefer serving as Co-Founder, President, CEO, and CSO, and Barbara Imperiali as co-founder and CTO. It has raised approximately $9.6 million across two exempt securities offerings in May 2021 and July 2023, and operates with an 11-50 employee base from its Delaware-incorporated entity.

AssayQuant Technologies firmographics

Firmographics
Name
AssayQuant Technologies
Legal name
AssayQuant Technologies, Inc.
Website
https://assayquant.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
AssayQuant Technologies develops continuous real-time kinase and phosphatase activity assays using its patented PhosphoSens fluorescent sensor peptide platform, selling assay kits, recombinant enzymes, and KinSight profiling services to pharmaceutical, biotechnology, and academic drug discovery teams.
Ownership category
akta.pro rank

AssayQuant Technologies industry classification

Industry
Product category
Drug Discovery Biochemical Assay Reagents
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAAAD
Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • Kinase activity assays
  • Phosphatase profiling services
  • Recombinant enzymes catalog
  • Continuous fluorescence assays
  • Drug discovery reagents

Where AssayQuant Technologies is headquartered

Location

Headquarters

HQ city
Marlborough
HQ country
United States
HQ region
North America

Offices1 record

Markets served

AssayQuant Technologies business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Assay Kit and Reagent Sales: Sale of biochemical kinase and phosphatase activity assay kits, sensor substrates, and recombinant enzymes. Products include PhosphoSens-Kinetic, PhosphoSens-Red, and PhosphoSens-Lysate formats along with enzyme reagents.
  2. KinSight Services: Contract research services for compound profiling including kinase selectivity profiling (400+ WT kinases), phosphatase selectivity profiling, time-dependent inhibition characterization, compound testing, and custom assay development.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goCatalog assay products available for direct purchase

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

AssayQuant Technologies product offering

Product offering

Core offering

AssayQuant Technologies develops and sells continuous kinetic biochemical assay products and contract research services for kinase and phosphatase drug discovery. Its core offering is the PhosphoSens Technology platform—fluorescent sensor peptide substrates that convert phosphorylation events into real-time fluorescent readouts—delivered through assay kits (PhosphoSens-Kinetic, PhosphoSens-Red, PhosphoSens-Lysate), a catalog of 1,100+ recombinant enzymes, and KinSight profiling services for compound selectivity and mechanism-of-inhibition characterization.

Product overview

AssayQuant Technologies offers a platform-plus-products architecture built on its proprietary PhosphoSens® Technology, which uses fluorescent sensor peptide substrates for continuous real-time measurement of kinase and phosphatase activity. The core platform is delivered through two assay formats: PhosphoSens-Kinetic (continuous fluorescence intensity for kinetic insight) and PhosphoSens-Red (time-resolved fluorescence for high-throughput screening), both supported by PhosphoSens-Lysate for cell/tissue lysate applications. These assay formats are available as individual product lines (Kinase Assays, Phosphatase Assays, Lysate Assays) and as part of a comprehensive recombinant enzyme portfolio spanning 900+ active kinases and 35+ phosphatases. Complementing the product catalog, KinSight Services apply the same PhosphoSens technology in AssayQuant's laboratory for compound profiling, selectivity assessment, and time-dependent inhibition characterization across hundreds of enzyme targets.

Differentiator

Problem solved

Functional benefit

Brands

  • PhosphoSens: Core technology platform for continuous enzyme activity measurement using fluorescent sensor peptide substrates
  • KinSight

Products and services

  • PhosphoSens-Kinetic Assays Continuous fluorescence intensity assay kits that generate real-time kinetic progress curves of kinase and phosphatase activity in every well, enabling drug discovery researchers to characterize inhibitor potency, reversibility, and mechanism of action.
  • PhosphoSens-Red Assays Time-resolved fluorescence assay kits optimized for high-throughput screening of compound libraries against kinase and phosphatase targets with reduced background interference.
  • PhosphoSens-Lysate Assays Continuous fluorescence assay kits for measuring kinase activity and cell signaling directly in unfractionated cell or tissue lysates and tissue homogenates without prior fractionation.
  • Kinase Assays Catalog line of validated kinase assay kits and reagents using PhosphoSens technology for real-time activity and inhibition measurement across multiple kinase targets and product configurations.
  • Phosphatase Assays Catalog line of continuous, real-time phosphatase activity assay kits with multiple configurations and customizable reagent options for drug discovery applications.
  • Lysate Assays Catalog line of assays using continuous fluorescence to measure kinase activity and cell signaling directly in unfractionated cell lysates and tissue homogenates.
  • Recombinant Enzymes High-purity, assay-validated recombinant kinase and phosphatase enzyme catalog (510+ wild type protein kinases, 420+ mutant protein kinases, 55+ lipid kinases, 35+ protein phosphatases) designed for integration with PhosphoSens assays in basic research and preclinical drug discovery.
  • KinSight Kinase Selectivity Profiling Contract research service that screens compounds against a panel of 400+ wild type protein kinases using continuous real-time PhosphoSens assays to characterize compound selectivity and mechanism of action.
  • KinSight Phosphatase Selectivity Profiling Contract research service that measures compound potency and selectivity across phosphatase targets using continuous enzyme activity assays.
  • Time-Dependent Inhibition Characterization Contract research service that quantifies inhibition kinetics and provides real-time data on inhibitor potency, reversibility, residence time, and inactivation kinetics using PhosphoSens assays.
  • Compound Testing Services Laboratory service for testing client-supplied compounds using PhosphoSens technology assays to measure compound potency and mechanism of inhibition.
  • Custom Assay Development Bespoke service that develops tailored kinase or phosphatase assays against client-specified targets in requested formats using the PhosphoSens technology.

Quantifiable outcome

  • Real-time measurement captures inhibitor dynamics and reversibility mechanisms not visible in endpoint reads

Companies that use AssayQuant Technologies

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles2 records

AssayQuant Technologies technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

AssayQuant Technologies partnerships and signals

Strategic signal

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

AssayQuant Technologies competitors and assessment

Company assessment

Direct peers

  • Eurofins DiscoverX: Offers KINOMEscan and related biochemical kinase/phosphatase profiling services and assays. Direct competitor to AssayQuant's KinSight selectivity profiling and kinase assay catalog.
  • Reaction Biology Corporation: Provides kinase and phosphatase selectivity profiling services, including time-dependent inhibition characterization. Highly comparable to AssayQuant's KinSight offering in target classes and use cases.
  • Carna Biosciences: Sells recombinant kinases, kinase assay kits, and kinase profiling services. Directly comparable to AssayQuant on recombinant enzyme portfolio and biochemical kinase assay product lines.
  • BPS Bioscience: Supplies recombinant enzymes, biochemical assay kits, and custom assay development services for kinase and other drug-discovery targets. Closely comparable to AssayQuant's product and custom assay service mix.
  • SignalChem Pharmaceuticals: Develops and sells recombinant kinases, assay kits, and profiling services. Overlaps directly with AssayQuant's enzyme catalog and kinase assay reagents.

Broad incumbents

  • Promega Corporation: Large life-science tools vendor offering kinase assay kits (e.g., ADP-Glo) and biochemical reagents. Competes in the same customer workflows but as part of a much broader portfolio.
  • Revvity: Successor to PerkinElmer's life sciences business, offering HTRF and LANCE kinase assay technologies. Competes directly with PhosphoSens formats in pharma screening labs.
  • Thermo Fisher Scientific: Sells SelectScreen kinase profiling services, LanthaScreen and Z'-LYTE kinase assay kits, and recombinant kinases. Competes across AssayQuant's product and service lines as part of a much larger portfolio.
  • Eurofins Scientific: Global CRO including Eurofins DiscoverX with broad kinase/phosphatase profiling capabilities. Competes with KinSight services but operates at significantly larger scale.
  • MilliporeSigma (Merck KGaA Life Science): Supplies kinase assay kits, recombinant enzymes, and profiling services through its life-science portfolio. Competes with AssayQuant in both catalog reagents and CRO services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

AssayQuant Technologies social profiles

Digital presence

AssayQuant Technologies financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AssayQuant Technologies leadership team

Management profile

Number of profiles

Profiles3 records

AssayQuant Technologies funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AssayQuant Technologies M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AssayQuant Technologies

What does AssayQuant Technologies do?

AssayQuant Technologies develops and sells continuous kinetic biochemical assay products and contract research services for kinase and phosphatase drug discovery. Its core offering is the PhosphoSens Technology platform—fluorescent sensor peptide substrates that convert phosphorylation events into real-time fluorescent readouts—delivered through assay kits (PhosphoSens-Kinetic, PhosphoSens-Red, PhosphoSens-Lysate), a catalog of 1,100+ recombinant enzymes, and KinSight profiling services for compound selectivity and mechanism-of-inhibition characterization.

Is AssayQuant Technologies a public or private company?

AssayQuant Technologies is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was AssayQuant Technologies founded?

AssayQuant Technologies was founded in 2015. It employs 11 to 50 people.

Where is AssayQuant Technologies based?

AssayQuant Technologies is headquartered in Marlborough, United States, in the North America region.

How does AssayQuant Technologies make money?

Two revenue lines are on record. Assay Kit and Reagent Sales are the primary driver. The others are kinSight Services.

Who are AssayQuant Technologies's main competitors?

Direct peers on record are Eurofins DiscoverX, Reaction Biology Corporation, Carna Biosciences, BPS Bioscience and SignalChem Pharmaceuticals. Broad incumbents are Promega Corporation, Revvity, Thermo Fisher Scientific, Eurofins Scientific and MilliporeSigma (Merck KGaA Life Science).

Does AssayQuant Technologies have an API?

No public API is recorded for AssayQuant Technologies.

What industry is AssayQuant Technologies in?

AssayQuant Technologies's product category is Drug Discovery Biochemical Assay Reagents. Its primary akta.pro industry code is HLAGAAAD, Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity), with a secondary code of HLAAAMAL, Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
SecSEC FORM DThe Securities and Exchange Commission filed a Form D for AssayQuant Technologies, Inc. indicating a securities offering amounting to $12 million, with $5,122,385 already sold. The offering is reported to not be in connection with any business combination transaction and has a mix of securities being offered, including debt.PR NewswireASSAYQUANT TECHNOLOGIES, INC. EXPANDS PANEL FOR KINOME PROFILING SERVICESAssayQuant Technologies, Inc. announced the expansion of its kinome profiling services to include a panel of 400+ unique kinases, comprising 399 wild-type and 2 mutant enzymes, along with custom panels featuring 28 protein phosphatases and 8 diacylglycerol lipid kinases. The expanded services leverage the company's proprietary PhosphoSens technology, which enables continuous monitoring of kinase activity and provides detailed compound selectivity assessments for drug discovery customers. The company, headquartered in Marlborough, Massachusetts, positioned this expansion as a step toward becoming a global leader in kinome and phosphatase profiling services.PR NewswireASSAYQUANT TECHNOLOGIES, INC. TO PRESENT AT BIOTECH SHOWCASE™ 2023AssayQuant Technologies, Inc. announced it will present at Biotech Showcase 2023, an investor conference held in San Francisco, with CEO Dr. Erik Schaefer providing a business overview of the company and its PhosphoSens technology. The proprietary technology enables direct quantitative monitoring of kinase and phosphatase activity for drug discovery applications, supporting the development of more effective therapeutics targeting these enzymes. Biotech Showcase, now in its 15th year, is a key networking event for life science entrepreneurs and investors during a major industry gathering week.BioSpaceVibliome Therapeutics and AssayQuant Technologies, Inc. Establish Collaborative RelationshipVibliome Therapeutics and AssayQuant Technologies announced a collaboration where AssayQuant will provide access to its PhosphoSens technology for kinome-wide profiling of Vibliome's small molecule Type II kinase inhibitors. The terms were not disclosed, but the partnership aims to accelerate Vibliome's drug development programs.SecSEC FORM DAssayQuant Technologies, Inc. filed a Form D with the SEC for an exempt offering of equity securities under Rule 506(b), with a total offering amount of $4,500,000 USD. The filing, dated May 14, 2021, indicates that nine investors had already participated in the offering which commenced on May 5, 2021.